23rd October 2019

To,

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400001

Dear Sir,

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, 5th Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Sandra (East) Mumbai - 400051

Sub: Board Meeting Intimation

Pursuant to clause 47 of the Listing Obligations and Disclosure Requirements Regulations,

2015 (LODR) we enclose advertisements given in Economic Times, Business Standard and

Maharashtra Times relating publication of financial results for quarter and half year ended

30th September 2019.

Thanking you,

Yours faithfully For GlaxoSmithKline Pharmaceuticals Limited

~l~ Ajay Nadkarni Vice President - Administration, Real Estate & Company Secretary

Encl: Public Notice

CIN No. L24239MH 1924PLC00 11 51

~~~ ~~"'l'lil

~ <llci.! ~Wlil . ~~f.1cqoo,m

~ -~~m<R 'RUIT-~'Wl'lJllffla . (~~ mfi \lJTJ f t.•1) ~~ --

0esrc1 UOU\UO {INr~:persnare} tnorennuB11seoJ..,_.....,,...._~-•~~~--,--~n r,,t,;~---~--~ -"~ - ~ --~:z.ou (Face-va_luo por Share of I_Nfl 10/- each)

Notes: t ~ · 1 The aforesaid unaudited ~lldated Flnanclal Rasulls and unaudited Standalone Financial Rosulls re reviewed by tho Audit Commlltoe and approved tiy tho

BoardofDlre1>1orsallhslqnt.~UngholdonOctober22,2019. ' ' • , _ • · 2 Thaabove Is an ox_tract_of iht_tlolslled formo_lof !He Unaudited Consolidated Financial Results and.Unaudl! Slondalone Flnencial ~•suits for the 11uarter and half year

e~d~September 30, 2019 led with the Stock Exclja!iges under Regulation 33 of tho SEBI (Lltting Obllg~ ns and Disclosure R'!Qulrements) Regula.lions, 2015. The fuD formal of the Financial R suits for the quarter and half year ended Seplember 30, 2019 la available on a webs he of tho Stock Exchanges www.nsalndla.com aQd www.~olndla.oom and on Iha _Company's )Yebsltawww.shardacropchem.oom

Place: M"umbal Date: Octo!Jer 22, 2019

- . ,I

",l\9~~

.... ,19,_ ",oo\919

t\i.,)(t .

"

¥on¥ ,196,~'ll•

l,.tl\,l\ 6,~)(,~

·tl\''~t

tlil,". • T (U19,)

~"116,)/6,

' t.oolll\9 too\S\ll

tl\~'l!t

~t,l".~ i..i..u,

"'(, Iii\~~, ¥~<.;~I\ 'l!t,(,19

t6.\'llt'

t\lS~ot

'll ~'II

~ !\It_

... 19",

... )$~

t ~~

For Sharda Cropchom Lh11ltod

~1\,-~l

' 'llo{til! •(\9f;,ql\,~

l\m~-S.t¥,19

-'6.\¥t

R.V.'Bubna · Chairman & Managing Director

,(DIN : 001365,68)

' ,

H,ln I

l\".~,19 ~l6.\

l\l~S,\ 'l!'l!".t,­~~\o

~6.~¥t

"llfff'lfll~(~)(ft•~)

~~~#r~~(f~ ~~~~~~ (.f.)1r-' -:--:--,-;F"-'--;'------;::;-'-'~~---,--,-~--r~~~-r----1v----~-;:::;:-~;;-+~-~·~'l!•---t-' - ' ='l!=,(,--'-1

~~.,o~'l"o!ll~~1 www._nselndJa.com ~ www.bselndJa.com

• • •• •- •--•••-- - -• _,.., ... '"'" ... .., ... ,,,.,.._. •v,,..,..,,.., ••110 -.,y ... ,....,,,,_,,_. VOi .._., I JYJ L.V f ... U\. I !VY Hotel "Lemon Tree•, Katra, J&K Respectively hrs at the venue mentioned at para 2 above. ·

a: · Date of opening of Commer<;lal Bids will be Intimated to technical qualified firms only after evaluatlon of technical quotes.

I.isl llflt Df Sullmlalon ol E-llld Online: 10" Dec. 2019'upto 15:00 Hrs.

9. Bidders are requested to offer their best discounted prices. 10. Purchaser reserves the right to reject any Tender Documents. 11.. Conditional Tenders wlli not be accepted.

Sd/ (Pardeep Kumar)

Director of Naval Armament for and on behalf of the President of India

For further delalls oflhe P/O)eci, please visit our webshe www.rtdo.lndlanral~ys.gov.ln or on Oi)roouremenl Port.I www.tenderwlzard.com/RLDA under the heading ·,-tend,~

For•ny dltlOCIUDOt ffllY OIIUI cont1d··

llole:• ""f Gornoendum or Addondum shall be publlshod onl/ on RLDA's Websi)e. davp 10702/11/0178/1920 DGM/fender, (M) 7703918078

• GlaxoSmithKline Pharmaceuticals Limited

. Registered Ofl)ce: Dr. Annie Besant Road, Mumbai 400030 • Website: www:gsk-india.com Email: askus@gsk.com • Corporate Identity Number: L24239MH1924PLC001151 . . . . .

., STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANGIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2019 ' .. I ~Lakhs)

~ Standalone I Consolidated Unaudited Unaudl(ed Unaudited Audited Unaudited Unaudited Unaudited Audited

Particulars Correepondlng Corresponding Three months Six months Year Ended Three months Six months Year Ended ended 30.09.19 ·ended 30,09.19 Three months 31.03.2019 · ended 30.09.19 ended 30.09.19 Three months 31.03.2019 . ended 30.09.18 ended 30.09.18

Revenue from Operations 88210 .. 167012 81631 312853 88202 166999 81631 312812

Profit before Exceptional Items . 18623 38226 16825 65882 18627 36238 16831 85397

Exceptional Items ·'

40114 40114 (1179) 489 40114 40114 (1179) 2869 , Profit before <ax 58737 76340 15646 66371 58741 7!,352 15652 68266

Net Profrt for the pertod I year 50279 61625 100TT 42536 50275 61629 10083 44539 ' Total comprehensive Income for the period soon 61423 10077 41987 50073 61427 10083 43990

Paid-up Equl(y Share Capital (Face value per share? 10) 16941 16941 16941 16941 16941 16941 16941 16941

~erEqul(y . 197301 197042

Earnings Per Share (EPS) (off 10 each)

Basic and diluted EPS after Exceptional Items ~ 29.68 36.38 5.95 25.11 29.68 36.38 5.95 26.29

Basic ~nd diluted EPS before Exceplional Items (fl 8.30 15:00 6 .40 25.07 I 8.30 15.00 6.40 24.85

Not Annualised Not Annualised

Notes: ·- I 1. The above Is an extract of the detailed format of the Unaudtted Financial Results for th~ quarter and six months ended 30" September, 2019 filed with the Stock Exchanges under Regulation 33 of the SEBI

(Listing Obligallons.and Disclosure Requirements) Regulations, 20j5. The full format of the said Financial Results are available on the website of the Company at www.gsk-lndla.com and on the website of Stock Exchanges at www.nselndla.com and www.bselndla.com .

2. Th~ above Results were reviewed by lhe Audit CommlUee and wer~ thereafter approved by the Board ofDlrectors al th~ir respective meetings held on 22"' October, 2019.

1

0

By Orderof the Board • Annaswamy Valdheesh

Managing Director DIN: 144430q f)

II.I

/.----------1.!!!a Gl,nxoSmithKline Pharmaceuticnls Limited ~ Re~1lstered Office: Dr.Annie Besant Road, Mumb~i 400030 • Websi!fi: 1~v.gsk-india.com

·t:mall: askus@gsk.com • Corporate Identity Number: L24239Mf f1924PLC001151

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED Fl~,IANCIAL RESULTS FOR . THE QIUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2019 ~ Lakhs)

Standalone Consolidated Unaudited Unaudited Unaudited Audited Unaudited Unaudited Unaudited Audited

Particulars Three Slxmont.hs Corresponding Th1ree Six months Corresponding li00nths Year Ended months Year Ended ended ended Three•months 31.03.2019 entl\ed

ended Three months 31.03,2019 30.09.19 30.09.19 ·enifed. 30.09.18 30.0! .19 30.09,19 ended 30.09.18

Revenue from Operations 88210 1!>7012 81631 312853 138202 166999 81631 312812

Profit before Exceptional Items 18623 36226 16825 65882 18627 36238 16831 65397

Exceptional Items 40114 40114 (1179) 489 ,40114 40114 (1179) 2869

Profit before tax 58737 76340 15646 66371 58741 76352 15652 68266

Net Profit for the period / year 50279 61625 10077 42536 50275 61629 100.83 44539

Total compre~enslve income for the period 50077 61423 10077 41987 50073 614V 10083 43990

Paid-up _Equity Spare Capital 16941 16941 16941 16941 16941 16941 16941 16941 (Face value per share ~ 10)

Other Equity . . 197301 . . . 197042

Earnings Per Share (EPS) (of~ 10 each)

Basic and diluted EPS after 29.68 36.38 5.95 25.11 29.68 36.38 5.95 26.29 Exceptional Items ~

Basic and diluted EPS before 8.30 15.00 6.40 25.07 8.30 15.00 , 6.40 24.85 Exceptional Items·~ - · Not Annualised Not Annualised

Notes: 1. The above Is an extract of the detailed format of the Unaudited Financial Results for the quarter and six months ended 30"' September, 2019 filed with the Stock Exchanges

under Regulation 33 6f the SEBI (Listing Obligalions and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the website of the Company at www.gsk-lndla.com and on the website of Stock Exchanges at www:nselndla.com and www.bselnd'la.com

2. The above Results were reviewed by the Aud it Committee and were theniafter approved by the Board of Directors at· their respective meelings held on 22"1 October, 2019. · '

Place: Mumbai 22rd Oct, 2019

P AP AUTOMOTIVE LIMITED CIN: L74899DL1995PLCO73281

Registered O ice: 54, Okhla Industrial Estate, Phase-Ill, New Delhi-110O2O Corporal Office: B-2O6A, Sector-81, Phase-II, Noida-2O13O5 (U.P.)

Tel +91 -120-2462552 / 53: Fax: +91-120-2461371

S.No. PARTICULARS Unaudl,.ted

1 Total income from operations (net) 8,538.66 . 17,765.0,4

2 Net profit for the period (before tax, ex1::eptional and/ or extraordinary items) 391.58 1 ,'227.8t)

3 Net profit for the period before tax (after exceptional and/ or 391.58 1,227.88 extraordinary items)

4 Net profit for the period after tax (aftm exceptional and/ or 432.28 ') ,008.22

By Order of the Board

Annaswamy Vaidheesh Managing Director

DIN: 1444303

. QUARTER ENDED 30.09.2018 .

11,887.94

1,656.89

1,656.89

1,156.81

I